Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2101-2107

  Agarwala, Sanjiv S ^a   Kirkwood, John M ^a   Gore, Martin ^a   Dreno, Brigitte ^a   Thatcher, Nicholas ^a   Czarnetski, Beate ^a   Atkins, Michael ^a   Buzaid, Antonio ^a   Skarlos, Dimosthenis ^a   Rankin, Elaine M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; ADULT; AGED; BRAIN TUMOR; DISEASE FREE SURVIVAL; FEMALE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 2942689983     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.044     Document Type: Article

References (31)

1. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
2. Lotze MT, Dallal RM, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT Jr, Hellman S. Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6) Philadelphia, PA, Lippincott Williams and Wilkins, 2001, pp 2012-2069
3. Kaba SE, Kyritsis AP, Hess K, et al: TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15: 1063-1070, 1997
4. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85:1599-1605, 1999
5. Richard MA, Grob JJ, Zarrour H, et al: Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Res 8:170-174, 1998
6. Stupp R, Ostermann S, Leyvraz S, et al: Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 20:59a, 2001 (abstr 232)
7. Yung WKA, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
8. Yung WKA, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
9. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
10. Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastalic melanoma. J Clin Oncol 13:910-913, 1995
11. Christodoulou C, Bafaloukos D, Kosmidis P, et al: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249-254, 2001
12. Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002
13. Paul MJ, Summers Y, Calvert AH, et al: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178, 2002
14. Margolin K, Atkins MB, Thompson JA, et al: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002
15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999
18. Hasegawa T, Kondziolka D, Flickinger JC, et al: Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy? Neurosurgery 52:1318-1326, 2003
19. Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6) Philadelphia, PA, Lippincott Williams and Wilkins, 2001. pp 2100-2160
20. Lee SM, Betticher DC, Thatcher N: Melanoma: Chemotherapy. Br Med Bull 51:609-630, 1995
21. Quantin X, Khial F, Reme-Saumon M, et al: Concomitant brain radiotherapy and vinorelbineifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 26:35-39, 1999
22. Abrey LE, Olson JD, Raizer JJ, et al: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001
23. Chapman PB, Einhorn LH, Meyers ML. et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
24. Atkins MB, Gollob JA. Sosman JA, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8:3075-3081, 2002
25. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998
26. Hargrave D, Stempak D, Coppes M, et al: Pilot study of oral continuous administration of low dose temozolomide in pediatric brain tumors. Proc Am Soc Clin Oncol 21:398a, 2002 (abstr 1590)
27. Raymond E, Vera K, Djafari L, et al: Safety profile and activity of high-dose temozolomide given daily × 3 every 2 weeks in patients with primary brain tumors. Proc Am Soc Clin Oncol 21:78a, 2002 (abstr 310)
28. Wurm RE, Roeschel L, Scheffler D, et al: Phase I-II study with continuous dose-escalated 21 day schedule temozolomide in recurrent high-grade glioma. Proc Am Soc Clin Oncol 19:164a, 2000 (abstr 634)
29. Balmaceda C, De Rosa C, Peterson K, et al: Multi-institutional trial of BID regimen of temozolomide for recurrent malignant gliomas. Proc Am Soc Clin Oncol 20:65a, 2001 (abstr 257)
30. Hwu W-J, Krown SE, Panageas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20:2610-2615, 2002
31. Hwu W-J, Krown SE, Lis E, et al: Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from maignant melanoma. Proc Am Soc Clin Oncol 22:720, 2003 (abstr 2894)